YZi Labs launches $1B Builder Fund to support BNB Chain projects
YZi Labs, formerly Binance Labs, has launched a $1 billion Builder Fund to accelerate innovation within the BNB ecosystem.
- YZi Labs launches a $1B Builder Fund to back founders in the BNB ecosystem.
- The fund targets projects in DeFi, AI, RWA, biotech, and Web3 infrastructure.
- BNB Chain hit record activity levels, averaging 26M daily transactions and new ATHs in price.
The initiative targets founders building on BNB Chain. It will support projects in decentralized finance, artificial intelligence, real-world assets, biotech, and decentralized science.
The move comes as BNB’s ( BNB ) network activity and price reach record levels, reflecting growing developer and user engagement.
Expanding builder support on BNB Chain
In its Oct. 8 announcement , YZi Labs said the new fund would offer both financial and technical support to teams building on BNB Chain’s fast and low-cost infrastructure. The program integrates with the EASY Residency accelerator and will now include BNB Chain’s Most Valuable Builder initiative as a dedicated track.
Builders accepted into the program can receive up to $500,000 in direct funding, along with access to YZi Labs’ network of mentors, investors, and technical experts.
To help founders connect globally, YZi Labs is also expanding its residency operations to New York, San Francisco, Dubai, and Singapore. The firm manages over $10 billion in assets and has supported more than 300 projects in 25 countries, including PancakeSwap, ListaDAO, Aster, and Aspecta.
Strengthening the BNB ecosystem
The launch follows several strong quarters for BNB Chain. The network now processes about 26 million transactions per day and leads in both decentralized exchange trading volume and daily active users.
BNB itself reached a new all-time high above $1,330 on Oct. 7. Recent upgrades, such as the Maxwell hardfork , improved performance further by cutting block times and reducing gas fees, making BNB Chain one of the most efficient major blockchains.
Ella Zhang, Head of YZi Labs, described BNB as “a living network with global reach and onchain depth,” adding that the fund’s mission is to back founders building tools that connect blockchain technology to real-world use.
The project marks another phase in the development of BNB Chain into a scalable platform for decentralized applications that support the emerging technology, finance, and artificial intelligence industries.
Applications for the EASY Residency and MVB Track are open, inviting builders to join the next phase of growth within the BNB ecosystem.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Anthropic files for IPO: lost $4.2 billion last year, revenue grew 12x to $4.6 billion, risk section warns of "threats to human survival"
Anthropic's IPO prospectus reveals that its spending on computing power and infrastructure will reach $7.33 billion in 2025, a twofold increase from 2024, accounting for more than half of its total operating expenses of $12.65 billion. The company plans to continue investing over $500 billion in the future. The risk section of the prospectus extends to 80 pages, explicitly warning that its AI models could pose "catastrophic or even existential threats," and may even resist shutdowns or manipulate information.
Meta shocks Wall Street by hiring MongoDB CEO and makes a high-profile entry into enterprise AI business
Meta has established an enterprise AI division called "Meta Enterprise Platform," which Mark Zuckerberg described as "the next important pillar." MongoDB CEO CJ Desai has been recruited to lead it. Analysts noted that Zuckerberg specifically poached a CEO from a publicly listed company to demonstrate the importance of this move. Desai's departure was announced just one day before Investor Day, with the timing surprising the public.
RBA set to hike interest rate to 4.60% in September as inflation remains elevated
AstraZeneca invests $2 billion in Summit, optimistic about Akeso's Ivose
This 18.6% premium subscription is not only a substantial endorsement, but both parties will also deeply collaborate on the joint development of combination therapies such as ADCs. The core of this deal is Akeso's Ivonescimab—the world’s first PD-1/VEGF bispecific antibody, and so far the only drug to have surpassed "K-drug" in head-to-head trials on both PFS and OS endpoints. The median OS reached 30.8 months, compared to 22.6 months for "K-drug", representing a 27% reduction in risk of death.
Crypto prices
More
